Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease

Jannis Kountourasa, Michael Doulberisab, Stergios A. Polyzosac, Panagiotis Katsinelosa

Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece; University Hospital Inselspital, Bern, Switzerland

aDepartment of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece (Jannis Kountouras, Michael Doulberis, Stergios A. Polyzos, Panagiotis Katsinelos), bDepartment of General Internal Medicine, University Hospital Inselspital, Bern 3010, Switzerland (Michael Doulberis), cFirst Department of Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece (Stergios A. Polyzos)

Correspondence to: Jannis Kountouras, MD, PhD, Professor of Medicine, Gastroenterologist, 8 Fanariou St, Byzantio 551 33, Thessaloniki, Macedonia, Greece, e-mail: jannis@auth.gr, ancoratus2010@gmail.com
Received 3 November 2018; accepted 11 December 2018; published online 15 January 2019
DOI: https://doi.org/10.20524/aog.2019.0349
© 2019 Hellenic Society of Gastroenterology

Annals of Gastroenterology (2019) 32, 214

In a recent article in this journal, Barroso et al [1] concluded that a high degree of abdominal obesity and sarcopenia in patients with medically refractory inflammatory bowel disease (IBD) signifies the potential importance of these findings in terms of the clinical course of IBD and the long-term effects, and thus should be investigated in future prospective studies.

In this respect, metabolic syndrome (MetS)—closely related to insulin resistance, the key component of MetS—is highly prevalent worldwide and its related morbidity include abdominal obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, nonalcoholic fatty liver disease, neurodegenerative diseases, cardio-cerebrovascular disorders, and malignancies, the endpoints of MetS [2-4]. Moreover, recent epidemiological evidence indicates that the prevalence of IBD and the rate of MetS-related obesity have increased substantially in the developed nations during the past half century, highlighting the significance of MetS in IBD patients [2,5]. Pathogenetic mediators in a milieu of chronic inflammation, inadequate immune response, oxidative stress, prothrombotic process, adipose tissue dysregulation, and changes in adipokines, involved in the MetS pathophysiology, could also be involved in the pathophysiology of IBD [2,6]. Specifically, all aforementioned MetS morbidities appear to contribute to IBD pathophysiology. For instance, obesity is connected with more active IBD and a reduction in the time span between diagnosis and surgery [5]; insulin resistance is associated with active and inactive IBD and offers evidence on the influence of inflammation and inflammation-related factors on arterial stiffening [7]; T2DM, IBD and colorectal cancer appear to share a common basis influenced by inflammatory processes, intestinal microbiota dysbiosis, and crosstalk between various signaling pathways [8]; and IBD patients have an increased risk of myocardial infarction, thromboembolic disorders (stroke), and cerebro-cardiovascular mortality, particularly during IBD activity [9]. Finally, since MetS is also associated with sarcopenia [10], the importance of these MetS-related parameters in terms of clinical IBD course and long-term outcomes should be investigated in future prospective studies.

References

1. Barroso T, Conway F, Emel S, et al. Patients with inflammatory bowel disease have higher abdominal adiposity and less skeletal mass than healthy controls. Ann Gastroenterol 2018;31:566-571.

2. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter 2015;20 Suppl 1:40-46.

3. Kountouras J, Polyzos SA, Katsinelos P, et al. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome:we consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol 2017;229:17-18.

4. Kountouras J, Polyzos SA, Doulberis M, et al. Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism 2018;87:18-24.

5. Gonçalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease:crosstalk between adipose tissue and bowel. Inflamm Bowel Dis 2015;21:453-467.

6. Michalak A, Mosińska P, Fichna J. Common links between metabolic syndrome and inflammatory bowel disease:current overview and future perspectives. Pharmacol Rep 2016;68:837-846.

7. Korkmaz H, Sahin F, Ipekci SH, Temel T, Kebapcilar L. Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2014;26:725-732.

8. Jurjus A, Eid A, Al Kattar S, et al. Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus:the links. BBA Clin 2015;5:16-24.

9. Filimon AM, Negreanu L, Doca M, Ciobanu A, Preda CM, Vinereanu D. Cardiovascular involvement in inflammatory bowel disease:dangerous liaisons. World J Gastroenterol 2015;21:9688-9692.

10. Zhang H, Lin S, Gao T, et al. Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults:a systematic review and meta-analysis. Nutrients 2018;10.

Notes

Conflict of Interest: None